POLH and triple-negative breast carcinoma: Very recent work involving functional screening has implicated POLH as an important target for the discovery and development of inhibitors in HORMAD1-positive triple-negative breast cancer (TNBC) [44], a defined disease group that comprises ~60% of TNBC cases, further encouraging the pursuit of POLH inhibitors.